Jim Cramer Applauds Johnson & Johnson’s “Great New Drug Profits, Triple-A Balance Sheet”
Key takeaways
- Cramer was bullish on the stock during the episode, as he said:
- Now, you can make good money for a while if you go all in on what’s hot, but I never do it because I know it’ll eventually blow up in your face… That’s why we run a diversified fund for the Investing Club.
- Well, the tsunami of data center selling is here, and today’s the day when I’m kind of patting myself on the back for keeping the Charitable Trust diversified, not going all in on the data center complex.
Jim Cramer Applauds Johnson & Johnson’s “Great New Drug Profits, Triple-A Balance Sheet” Syeda Seirut Javed Wed, June 10, 2026 at 6:36 PM GMT+7 2 min read JNJ Johnson & Johnson (NYSE:JNJ) was among the stocks Jim Cramer discussed on Mad Money, along with the recent sell-off in the market. Cramer was bullish on the stock during the episode, as he said:
Now, you can make good money for a while if you go all in on what’s hot, but I never do it because I know it’ll eventually blow up in your face… That’s why we run a diversified fund for the Investing Club. When you’re diversified, at any given moment, you’re going to own some losers, though, or at least some stocks that aren’t working. These stocks will lag while the data center roars, but they preserve your sanity when you get a tsunami-like sell-off in the hottest stocks out there.
Well, the tsunami of data center selling is here, and today’s the day when I’m kind of patting myself on the back for keeping the Charitable Trust diversified, not going all in on the data center complex. Today’s the day when we’re grateful for our Johnson & Johnson position. Great new drug profits. Triple-A balance sheet, better than the United States… See, the lesson’s clear, people. The P&Gs and the J&Js in your portfolio allow you to safely own the techs. They’re kind of like permits. But if you don’t take something off the table of the techs when you’re up big, I think you’re going to live to regret it.